

Drugs and Therapeutics (D & T) Committee
Meeting Results
August 14, 2019

Drug Name	Review Type	Committee Recommendation	Prior Approval Status – Final Determination
Nuzyra	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Oxervate	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Siklos	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
Ultomiris	New Drug Initial Review	Non-preferred requires PA	Non-preferred requires PA
DoVato	New Drug Initial Review	Preferred, no PA	Preferred, no PA
Xeljanz	New Drug Appeal	Non-preferred requires PA	Non-preferred requires PA
Aimovig	New Drug Appeal	Preferred with PA	Preferred with PA
Mitigare	New Drug Appeal	Non-preferred requires PA	Non-preferred requires PA
Dyanavel XR	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA
Quillichew ER	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA
Quillivant XR	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA
Zepatier	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA
Granix	PDL Appeal	Non-preferred requires PA	Non-preferred requires PA